45 results about "Haemostatic agent" patented technology

The invention relates to a modified starch material for biocompatible hemostasis, biocompatible anti-adhesion, tissue healing promotion, absorbable surgery sealing and tissue adhesion. The invention applies biocompatible modified starch to animal tissues, wherein the modified starch material has the molecular weight of more than 15,000 daltons, and the particle diameter of between 1 and 1,000 mu m. The modified starch hemostatic material has stypticity, reduces hemorrhage, blood oozing and tissue fluid oozing of wounds, maintains relative moistening or drying of wound surfaces or the wounds, inhibits bacterium growth and inflammation reaction, and contributes to locally diminish inflammation of the wounds and relieve pain of patients. Moreover, the modified starch material can wash local parts after operation is over and remove redundant modified starch which does not participate in hemostasis, and can easily remove haemostatic under the condition of debridement treatment after self-help and first-aid treatment of war wounds; and hemostatic materials with a small amount of modified starch can be absorbed by the body, so that the pain of tearing of gauzes and bandages on people is avoided.

A gingival retraction material and method of fabrication. The material comprises a carrying medium, retraction medium, and an anti-evaporation component. Preferably the carrying and retraction media are a clay such as kaolin, and the anti-evaporation component is glycerin. Additional components may be added to the material such as aluminum chloride, aluminum sulfate, ferric chloride, ferric subsulfate, styptics, haemostatic agents, coagulants coloring and flavoring. The material may be packaged in a kit with components to apply the material. Further disclosed is the method for making the material. Also disclosed is a delivery system for medication that includes a carrying medium, anti-evaporation component and a medication.

A haemostatic kit to be used as a medical device provides for a containment unit and a haemostatic agent in said containment unit, said haemostatic agent occupying less than 90% of the volume of the containment unit. This allows for facile and consequently sterile preparation of, for instance, a gelatin paste for use in haemostatis when combined with saline, thrombin or another agent to assist in haemostatis.

A hydrogel tissue adhesive having increased degradation time is described. The hydrogel tissue adhesive is formed by reacting an oxidized polysaccharide with a water-dispersible, multi-arm amine in the presence of a polyol additive, which retards the degradation of the hydrogel. The hydrogel may be useful as a tissue adhesive or sealant for medical applications, including but not limited to, ophthalmic applications such as sealing wounds resulting from trauma such as corneal lacerations, or from surgical procedures such as vitrectomy procedures, cataract surgery, LASIK surgery, glaucoma surgery, and corneal transplants; neurosurgery applications, such as sealing the dura; as a plug to seal a fistula or the punctum; adhesion prevention to prevent undesired tissue to tissue adhesions resulting from trauma or surgery; and as a hemostat sealant.

The invention relates to an external natural zeolite emergency survival haemostatic which adopts a natural zeolite haemostatic or a modified natural zeolite haemostatic directly; the raw materials of the natural zeolite comprises the following components: silicon oxide, aluminum oxide, titanium oxide, ferric oxide, magnesium oxide, calcium oxide, sodium oxide and potassium oxide; wherein, the total content of the silicon oxide and the aluminum oxide is more than 70 percent; the aperture of the natural zeolite is 0.3 to 0.2nm, the specific surface area is 30 to 1,000m<2>/g and the pore volume is 0.2 to 1.0cm<3>/g, and the diameter of particles of the natural zeolite haemostatic is 1mum to 1mm. The preparation method is simple and the hemostatic effect is good, thus being used for hemostasis in different medical situations.

The present invention relates to plasma-based films and in particular to flexible plasma-based films. The invention further relates to and to methods of making and using the flexible plasma-based films. Embodiments of the invention have been particularly developed for making flexible plasma-based films useful as a hemostat in the treatment and/or prevention of mild to severe as well as arterial bleedings, as an anti-adhesive sheet to reduce or prevent development of surgery-induced adhesions, as a wound healing patch, as a wound dressing, or as a film useful in hernia repair. Embodiments of the invention will be described hereinafter with reference to these applications. However, it will be appreciated that the invention is not limited to this particular field of use.

The invention relates to a rapid haemostat using mipor starch with a high specific surface area as a main raw material and a preparation process thereof. The rapid haemostat capable of being absorbed by a human body is prepared by using the mipor starch with the high specific surface area as the raw material and adding growth factors stimulating the rapid healing of a wound and an antimicrobial with diminish inflammation and infection-resistant effects. The haemostat not only can more rapidly and effectively arrest bleeding, but also can effectively accelerate the healing, the diminish inflammation and the infection resistance of the wound.

The present invention is the development of haemostatic compositions that use nitrogen containing organic polymers in combination with haemostatic agents to create a gel form. Compositions utilizing the polymers exhibit relatively lower concentrations of haemostatic agents, drawing benefits from such lower concentrations as they limit unwanted side effects of the haemostatic agents. Preferred compositions utilize Poly(N-vinylpyrrolidone), Poly(2-ethyl-2-oxazoline) as thickening agents and ferric sulfate as an active ingredient.

The present invention provides a preparation method of an external-use ophicalcitum compound emergency hemostat. The present invention grinds the natural ophicalcitum into a certain particle diameter, carries out the calcium chloride modification treatment through different temperature treatments, and obtains the ophicalcitum compound material with high hematopoietic function by mixing with other auxiliary compound materials. The present invention can be used for hemostasis on different medical occasions, can be combined with other medical materials and medical apparatuses, can be made into adhesive bandage, transfusion bandage, self-adhesive dressing, tablet and capsule core material, operation packet, first-aid packet, etc., and can also be made as the oral medicine and be used with other external-use medicines so as to get better curing effect. The present invention has the advantages of simple and feasible operation, abundant materials, low price and easy access, convenient application, good hematopoietic effect and less discharged heat.

The invention provides a dental device comprising a sheath for fitting over a tooth, the sheath carrying a haemostatic agent in at least one region thereof, wherein the sheath comprises a generally cylindrical body having at least a first end and a second end, at least one of said first and second ends presenting a circumferential margin carrying at least part of the haemostatic agent, and wherein the at least one end carrying at least part of the haemostatic agent is open to a cavity and the other end is closed. A method of inhibiting or preventing gingival bleeding and a method of retracting gingivae using such a device are also provided.

The invention discloses a rapid hemostatic product for clinical operation wounds, as well as a preparation method and application of the rapid hemostatic product. The rapid hemostatic product comprises a matrix containing a microbial transglutaminase (mT6), wherein the amino acid sequence of the transglutaminase is the protein sequence coded by the gene shown in SEQ ID NO.: 3, or the protein sequence shown in SEQ ID NO.: 4. Specifically, the rapid hemostatic product is selected from a hemostatic, a hemostatic device, a hemostatic first-aid kit or a common hemostatic product; the matrix adopts a fluid or semisolid form, which can be absorbed by a human body, or a plastic gel or colloid form. The rapid hemostatic product contains the microbial transglutaminase and gelatin. The rapid hemostatic product has the advantages of rapid hemostatic property, convenience for use, prevention on organ adhesion, promotion on wound healing, low toxic and side effects, complete absorption and the like. The rapid hemostatic product can be used as a medical hemostatic material or product for clinical operation wounds, can stop bleeding rapidly, prevents organ adhesion, is easy to absorb, has little possibility of spreading diseases, and is low in cost.

Provided is a tunable biopolymer hydrogel produced from two processed natural polysaccharides for use as a hemostat. If desired, the hydrogel formation can be tuned so that the hydrogel forms within seconds when applied to a tissue lesion. The resulting hydrogel can adhere to tissue and, without swelling, produce hemostasis within seconds after application to tissue of interest. The hydrogel also captures, aggregates and concentrates platelets and red blood cells at the site of the tissue lesion thereby initiating a clotting cascade at the site of the lesion. The hemostat can be used to prevent blood loss during surgical procedures, for example, during brain, spine or other surgical procedures where hemostasis is desirable, and is particularly useful during surgical procedures where swelling of the hemostat (e.g., in the brain or spine) would be detrimental to the subject.

A microstructured hemostat comprising multiple layers of microstructure, each layer characterized by one or more length scales, is described. Microstructured hemostats of the present invention, can reduce the time for blood coagulation, control the morphology of the coagulation, and provide a novel diagnostic platform for evaluation of coagulation function from a morphological perspective.